A Systemic Hyperthermia Oncologic Working Group Trial

Anneke M. Westermann(Amsterdam UMC Location University of Amsterdam), H. Ian Robins(University of Wisconsin–Madison), W. Longo(University of Wisconsin–Madison), Howard H. Bailey, Dörthe M. Katschinski(University of Göttingen), Cynthia L. Tiggelaar(University of Wisconsin–Madison), Antje Neumann(Krankenhaus Nordwest), A. Bakhshandeh(University of Lübeck), P. Zum Vörde Sive Vörding(Amsterdam UMC Location University of Amsterdam), Elke Jäger(Krankenhaus Nordwest), J.D.P. van Dijk(Amsterdam UMC Location University of Amsterdam), W. Gillis, Alexander Knuth(National Center for Cancer Care and Research), G. Wiedemann(University of Lübeck), S. Peters, Dirk Jäger(Memorial Sloan Kettering Cancer Center), J. Emanuel Finet(University of Wisconsin–Madison)
Oncology
January 1, 2003
10.1159/000070287
Cited by 30

Related Papers

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
|Journal of Clinical Oncology|2008|784
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
|The Lancet Oncology|2016|738
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer
|JAMA Oncology|2017|473
Classification of current anticancer immunotherapies
|Oncotarget|2014|469